2025
Cold and hot fibrosis define clinically distinct cardiac pathologies
Miyara S, Adler M, Umansky K, Häußler D, Bassat E, Divinsky Y, Elkahal J, Kain D, Lendengolts D, Flores R, Bueno-Levy H, Golani O, Shalit T, Gershovits M, Weizman E, Genzelinakh A, Kimchi D, Shakked A, Zhang L, Wang J, Baehr A, Petrover Z, Sarig R, Dorn T, Moretti A, Saez-Rodriguez J, Kupatt C, Tanaka E, Medzhitov R, Krüger A, Mayo A, Alon U, Tzahor E. Cold and hot fibrosis define clinically distinct cardiac pathologies. Cell Systems 2025, 16: 101198. PMID: 39970910, PMCID: PMC11922821, DOI: 10.1016/j.cels.2025.101198.Peer-Reviewed Original ResearchConceptsHeart failureMyocardial infarctionAutocrine growth factor loopsUnmet medical needCardiac fibrosisNeutralizing antibodiesReduced fibrosisTreatment strategiesMyofibroblast proliferationAcute MIFibrosis post-MICardiac pathologyFibrosisTherapeutic approachesPost-MIChronic injuryMyofibroblastsMedical needFactor loopsInterleukin-10 exhibit dose-dependent effects on macrophage phenotypes and cardiac remodeling after myocardial infarction
Zhang J, Rizk R, Li X, Lee B, Matthies M, Bietz K, Kim K, Huard J, Wang Y, Chen W. Interleukin-10 exhibit dose-dependent effects on macrophage phenotypes and cardiac remodeling after myocardial infarction. Frontiers In Physiology 2025, 15: 1481460. PMID: 39882328, PMCID: PMC11774956, DOI: 10.3389/fphys.2024.1481460.Peer-Reviewed Original ResearchIL-10 treatmentIL-10Dose-dependent effectMyocardial infarctionPost-MICardiac remodelingInterleukin-10Lower LV ejection fractionDoses of IL-10LV ejection fractionIL-10 administrationMyocardial gene expressionExogenous IL-10IL-10 secretionEffective dose rangePhenotypic transitionDose-dependent mannerLV fibrosisEjection fractionMouse MI modelCardiac functionCell infiltrationImmunomodulatory cytokinesContractile functionDose-dependently
2024
Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis
Y K, Lee P, Chowdhury I, Schwartz R, Kang Y, Mangalesh S, Babapour G, Akman Z, Chang Y, Song J, Lessa Y, Damluji A, Nanna M, Nanna M. Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis. European Heart Journal 2024, 45: ehae666.1640. DOI: 10.1093/eurheartj/ehae666.1640.Peer-Reviewed Original ResearchRandomized Controlled TrialsReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitReduced EFMeta-RegressionEF patientsPreserved EFBB usersReperfusion eraMeta-analysisSubgroup analysisSystematic reviewPost-MIPost-MI careEffect of beta-blockersIncreased all-cause mortalityHistory of HFEvent-free periodAll-Cause MortalityTemporal trendsStudy inclusion periodModern randomized controlled trialsBeta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis
Chi K, Lee P, Chowdhury I, Akman Z, Mangalesh S, Song J, Satish V, Babapour G, Kang Y, Schwartz R, Chang Y, Borkowski P, Nanna M, Damluji A, Nanna M. Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis. European Journal Of Preventive Cardiology 2024, 32: 633-646. PMID: 39298680, PMCID: PMC11922798, DOI: 10.1093/eurjpc/zwae298.Peer-Reviewed Original ResearchReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitBB useReduced EFCV mortalityPost-MIRandom-effects meta-analysisMeta-analysisHistory of HFAll-Cause MortalityTemporal trendsPrespecified subgroup analysesEvent-free periodCardiovascular (CVIncreased CV mortalityStudy inclusion periodPost-myocardial infarctionContemporary dataAssociated with detrimental effectsNon-significant trendSecondary preventionBB users
2022
Regional heterogeneity in determinants of atrial matrix remodeling and association with atrial fibrillation vulnerability postmyocardial infarction
Stacy MR, Lin BA, Thorn SL, Lobb DC, Maxfield MW, Novack C, Zellars KN, Freeburg L, Akar JG, Sinusas AJ, Spinale FG. Regional heterogeneity in determinants of atrial matrix remodeling and association with atrial fibrillation vulnerability postmyocardial infarction. Heart Rhythm 2022, 19: 847-855. PMID: 35066183, PMCID: PMC9064890, DOI: 10.1016/j.hrthm.2022.01.022.Peer-Reviewed Original ResearchConceptsAtrial fibrillationMyocardial infarctionRight atrial regionsAtrial regionsPost-MIMMP activityMatrix metalloproteinasesMMP/TIMP profilesNew-onset atrial fibrillationLeft atrial regionsMMP/TIMP expressionLeft atrial appendageMatrix remodelingElectrical stimulation protocolFibrillar collagen contentExtracellular matrix remodelingAF vulnerabilityTIMP profilesAtrial appendagePostmyocardial infarctionMyocardial substrateStimulation protocolNoninvasive molecular imagingTIMP expressionTissue inhibitor
2009
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial
Piccini JP, Zhang M, Pieper K, Solomon SD, Al-Khatib SM, Van de Werf F, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. European Heart Journal 2009, 31: 211-221. PMID: 19854729, DOI: 10.1093/eurheartj/ehp425.Peer-Reviewed Original ResearchConceptsSudden cardiac deathMyocardial infarctionInitial left ventricular ejection fractionRisk of SCDLeft ventricular ejection fractionHigher baseline heart rateBaseline creatinine clearanceBaseline clinical characteristicsRecurrent cardiovascular eventsPrior myocardial infarctionVentricular ejection fractionBaseline heart rateCox proportional hazardsCardiovascular eventsClinical characteristicsCreatinine clearanceCumulative incidenceCardiac deathEjection fractionEntire followRisk stratificationVALIANT trialPost-MIRisk stratifierLandmark analysis
2005
Therapies to prevent heart failure post-myocardial infarction
Thomas KL, Velazquez EJ. Therapies to prevent heart failure post-myocardial infarction. Current Heart Failure Reports 2005, 2: 174-182. PMID: 16332310, DOI: 10.1007/bf02696647.Peer-Reviewed Original ResearchConceptsPost-MI heart failureHeart failureMyocardial infarctionPresence of HFHeart failure post-myocardial infarctionEvidence-based medicationsMortality of patientsOutcomes of patientsVentricular systolic dysfunctionLower blood pressureTreatment of patientsAcute myocardial infarctionPost-myocardial infarctionKillip classSystolic dysfunctionCommon complicationBlood pressureClinical factorsRevascularization proceduresInfarct sizePoor prognosisPatient populationMale genderPost-MIRisk factors
2004
Evaluation of myocardial matrix metalloproteinase (MMP) mediated post-MI remodeling with a novel radiolabeled MMP inhibitor
Su H, Spinale F, Dobrucki1 L, Chow C, Sweterlitsch S, Hu X, Bourke B, Cavaliere P, Hua J, Azure M, Edwards D, Sinusas A. Evaluation of myocardial matrix metalloproteinase (MMP) mediated post-MI remodeling with a novel radiolabeled MMP inhibitor. Journal Of Nuclear Cardiology 2004, 11: s20. DOI: 10.1016/j.nuclcard.2004.06.063.Peer-Reviewed Original ResearchMyocardial infarctionPost-MI remodelingPost-myocardial infarctionMMP activationMMP inhibitorsControl groupSitu zymographyMyocardial matrix metalloproteinasesMI regionMin post injectionControl miceMI miceVentricular remodelingPost-MIMI groupMurine modelNew therapiesMatrix metalloproteinaseMMP activityMatrix metalloproteinasesShort-axis slicesMI areaPost injectionMyocardial retentionMice
1995
768-6 Lipid Rich Plaques with Thrombus are Common in Unstable Rest Angina: Observations from Atherectomy Tissue Analysis
Sharma S, Fyfe B, Bongu R, Asnes J, Marmur J, Cocke T, Almeida O, Ambrose J. 768-6 Lipid Rich Plaques with Thrombus are Common in Unstable Rest Angina: Observations from Atherectomy Tissue Analysis. Journal Of The American College Of Cardiology 1995, 25: 281a. DOI: 10.1016/0735-1097(95)92624-e.Peer-Reviewed Original ResearchUnstable rest anginaRest anginaDirectional coronary atherectomyLipid plaquesAcute MIFibrous plaquesInflammatory cellsAutopsy studyPost-MIRich plaquesPlaque compositionDe novo culprit lesionsLipid-rich plaquesCulprit lesionStable anginaCoronary atherectomyNew onsetAcute syndromeClinical presentationCoronary thrombusPathogenetic linkCommon pathogenesisPathological dataAnginaTissue analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply